Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors
(low-grade astrocytomas) in children and adults. Previous research has given us a better
understanding of this type of tumor by studying the genetic "make-up" of LGAs. From this
research, the investigators found that a drug called sorafenib may stop the growth of tumor
cells by blocking some of the molecules needed for cell growth and by blocking blood flow to
the tumor. This trial is studying how well sorafenib works in treating patients with LGAs,
and how the effects relate to the specific genetic "make-up" of your particular tumor. This
testing of your tumor's genetic make-up is optional and requires available tumor tissue for
testing. In summary, the aims of this study are: To see if sorafenib can shrink LGAs; how
well sorafenib is tolerated in patients with LGAs; and, how the effects of sorafenib relate
to the genetic make-up of individual LGAs (Optional Study)
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health